[{"orgOrder":0,"company":"Prothena","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PRX005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Prothena","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"PRX005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PRX012","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PRX012","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PRX012","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Inflazome","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Inzomelid","moa":"NLRP3","graph1":"Neurology","graph2":"Phase I","graph3":"Inflazome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inflazome \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Inflazome \/ F. Hoffmann-La Roche"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Under the collaboration, Bristol will obtain the exclusive worldwide commercial rights for PRX005, a best-in-class anti-tau antibody that specifically binds with high affinity the R1, R2, and R3 repeats within the MTBR of tau and targets both 3R and 4R t...

                          Product Name : PRX005

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          November 07, 2023

                          Lead Product(s) : PRX005

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Bristol Myers Squibb

                          Deal Size : $2,200.0 million

                          Deal Type : Collaboration

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : PRX005 is an anti-tau antibody that specically binds with high anity the R1, R2, and R3 repeats within the MTBR of tau and targets both 3R and 4R tau isoforms. Neurobrillary tangles composed of misfolded tau proteins, with amyloid beta plaques in alzheim...

                          Product Name : PRX005

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          January 31, 2023

                          Lead Product(s) : PRX005

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Bristol Myers Squibb

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Preclinical data have also demonstrated clearance of both pyroglutamate modified and unmodified Aβ plaque in brain tissue at concentrations of PRX012 estimated to be clinically achievable in the central nervous system with subcutaneous delivery.

                          Product Name : PRX012

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 26, 2022

                          Lead Product(s) : PRX012

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Preclinical data have shown that PRX012 binds to beta amyloid plaques and oligomers with high avidity, enabling effective levels of Aβ plaque occupancy at relatively lower dose ranges, which are optimal for subcutaneous delivery.

                          Product Name : PRX012

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 28, 2022

                          Lead Product(s) : PRX012

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The acquisition gives Roche full rights to Inflazome’s entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors.

                          Product Name : IZD174

                          Product Type : Other Small Molecule

                          Upfront Cash : $441.9 million

                          September 21, 2020

                          Lead Product(s) : Inzomelid

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : F. Hoffmann-La Roche

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank